Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs

Anemia in CKD is associated with poor CV outcomes, increased risk of CKD progression, decreased health-related quality of life (HRQOL), and increased healthcare resource utilization. Erythropoiesis-stimulating agents have been the standard of care for treating anemia in CKD but are associated with CV safety concerns; other therapies include red blood cell transfusions and iron administration but each potentially has severe adverse events. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are promising novel agents in development for treating CKD-associated anemia. These oral agents increase endogenous erythropoietin production, improve iron absorption and mobilization, and decrease hepcidin production in the liver.

Share

Program Content

Activities

  • Current Management and Potential Role of HIF-PHIs
    Anemia in Patients with CVD and CKD: Current Management and Potential Role of HIF-PHIs
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 16, 2022

    Expires: November 16, 2023

Provided by

ProCE Banner
ProCE Banner

Jointly provided by USFH and Rockpointe

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline